Drug-Eluting Balloons

This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.

Technology | Drug-Eluting Balloons

September 26, 2016 — C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational ...

Home September 26, 2016
Home
News | Drug-Eluting Balloons

September 22, 2016 — New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the ...

Home September 22, 2016
Home
Technology | Drug-Eluting Balloons

September 19, 2016 — Medtronic plc announced that the U.S. Food and Drug Administration (FDA) approved the IN.PACT ...

Home September 19, 2016
Home
VIVA 2016, late breaking trials, cath lab
Feature | Cath Lab

Vascular Interventional Advances (VIVA) 2016 released its list late-breaking research presentations in vascular ...

Home September 14, 2016
Home
Technology | Drug-Eluting Balloons

July 18, 2016 — Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug ...

Home July 18, 2016
Home
News | Drug-Eluting Balloons

June 3, 2016 — Cardionovum GmbH recently announced the completion of enrollment of the RAPID trial. Results will be used ...

Home June 03, 2016
Home
Intact Vascular, Tack Endovascular System
Feature | Peripheral Artery Disease (PAD) | Dave Fornell

It is estimated that more than 10 million people in the United States are affected by peripheral arterial disease (PAD) ...

Home February 22, 2016
Home
News | Drug-Eluting Balloons

January 18, 2016 — Medtronic plc announced that the IN.PACT Admiral drug eluting balloon (DEB) has received CE ...

Home January 18, 2016
Home
ISAR-DESIRE 4 trial, TCT 2015, drug-coated balloon, DCB, scoring balloon, SCB, drug-eluting stent restenosis
Feature | Drug-Eluting Balloons

October 22, 2015 — Results from the ISAR-DESIRE 4 trial indicate that use of a scoring balloon plus a paclitaxel-coated ...

Home October 22, 2015
Home
IN.PACT SFA study, TCT 2015, drug-coated balloons, PTA, SFA disease, superficial femoral artery
Feature | Peripheral Artery Disease (PAD)

October 18, 2015 — Two-year results from the IN.PACT SFA study found the use of a drug-coated balloon was superior to co ...

Home October 18, 2015
Home
News | Drug-Eluting Balloons

October 15, 2015 — C. R. Bard Inc. announced the presentation of the 12-month results from the Lutonix Global Real-World ...

Home October 15, 2015
Home
News | Cath Lab

August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report ...

Home August 26, 2015
Home
C.R. Bard, LEVANT 2 results, Lutonix 035 DCB, drug coated balloon, PTA
Feature | Drug-Eluting Balloons

July 8, 2015 - C.R. Bard Inc. announced the publication of results from the LEVANT 2 study in the June 24, 2015, online ...

Home July 08, 2015
Home
News | Drug-Eluting Balloons

June 11, 2015 - C.R. Bard Inc. announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has improved the ...

Home June 11, 2015
Home
News

May 22, 2015 — New clinical data from two different studies show the IN.PACT Admiral drug-coated balloon from Medtronic ...

Home May 22, 2015
Home
Subscribe Now